Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes.

Juris J MeierCharlotte GranhallUlrike HoevelmannAndrea NavarriaLeona Plum-MoerschelChethana RameshAndrea TannapfelChristoph Kapitza

Published in: Diabetes, obesity & metabolism (2022)

There was no significant difference in exposure to oral semaglutide in subjects with or without upper GI disease, hence no dose adjustment is required.

Keyphrases